In Silico, In Vitro, and rhesus macaque study showing that azvudine (FNC) alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase (MPO) and reducing neutrophil extracellular trap (NET) formation. Authors demonstrated FNC's dual action as both an antiviral and anti-inflammatory agent in SARS-CoV-2 infected rhesus macaques, effectively reducing neutrophil infiltration and inflammatory injury. Using mass spectrometry-based proteomics, LiP-MS, CETSA, and Co-IP analyses, authors identified MPO as FNC's therapeutic target and confirmed its effects on NET formation in both rhesus macaque tissues and differentiated HL-60 cells. The findings suggest FNC could be particularly valuable for treating both acute COVID-19 and long COVID, where NETosis serves as a clinical biomarker of disease severity.
3 preclinical studies support the efficacy of azvudine for COVID-19:
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.